Posters NCHIV 2016


Abstract number Abstract title Presenting author
P01 Development and validation of a risk score to assist screening for acute HIV-1 infection among men who have sex with men Dijkstra
P02 Frequency of STI testing associated with sexual risk behavior and HIV serostatus among MSM in the Netherlands Reitsema
P03 In the Heat of the Moment: Towards a Dual Process Model of Sexual Risk Behavior Wolfs
P04 Using Lorenz Curves to Study the Impact of Heterogeneity in Sexual Behavior on the Distribution of HIV Infection Alsina
P05 Blended-learning training on HIV care and treatment reduces stigma and can improve retention of PLWHA in care de Lange
P06 Health related quality of life of HIV-infected patients in care in the Netherlands: A cross-sectional assessment of patient related factors, and comparison with other chronic diseases Nieuwkerk
P07 HIV-stigma, depression, and social support: opportunities for improving quality of life among Dutch people living with HIV den Daas
P08 Feasibility and results of the EuroQol 5 dimension quality of life questionnaire among HIV-positive individuals at an outpatient clinic Popping
P09 A sexual behavior risk score for HIV infection during sexual careers in men who have sex with men Basten
P10 RANTES, CD169/Siglec-1 and CD38-HLADR are Independently Associated with CXCR4-tropism in treatment naïve HIV-1 subtype C infected Individuals Connell
P11 The Alere HIV Combo Point-of-Care-test: Useful for detection of early HIV-1 infections? Götz
P12 Viral load metrics: an additional benefit for HIV surveillance? Heijne
P13 Modeling population viral load metrics for monitoring impact of treatment as prevention Rozhnova
P14 Increasing role of young MSM to HIV epidemic spread and renewal Ratmann
P15 Several national HIV-1 non-B subtype sub-epidemics established in the Netherlands Bezemer
P16 HIV-1 envelope glycoprotein vaccines based on viral sequences from elite neutralizers of the Amsterdam Cohort Study Schorcht
P17 The feasibility of dose reduction of efavirenz in pregnant women – A physiologically-based population pharmacokinetic analysis ter heine
P18 Novel INSTI GS-9883 10 Day Monotherapy in HIV-1 Infected Subjects Pistoor
P19 Multicenter analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure Boerma
P20 Efficacy and Safety of Tenofovir Alafenamide (TAF) vs Tenofovir DF in HIV-infected Virologically Suppressed Older Adults: Subgroup Analysis of a Randomized Switch Study de Groen
P21 Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4 T-cell count at 96 weeks ART Pasternak
P22 Suboptimal immune recovery in HIV-1 infected individuals in Sub-Saharan Africa despite long-term suppressive antiretroviral therapy Kroeze
P23 Despite a decreasing rate of virological failure in the treated Dutch HIV-infected population, transmitted HIV drug resistance in the Netherlands remains stable van Litsenburg
P24 Drug-resistant HIV-1 during long-term second-line antiretroviral treatment in Kenya: The advent of untreatable HIV in resource-limited settings? Inzaule
P25 High Rates of transmission of drug-resistant HIV in Aruba resulting in reduced susceptibility to the WHO recommended first-line regimen in nearly half of newly diagnosed HIV-infected patients Hofstra
P26 Increasing understanding of non-use or inconsistent use of ART: A multifactorial assessment highlighting the importance of patient beliefs and abilities de Wit
P27 Peer support of migrant people living with HIV in the Netherlands increases treatment adherence Been
P28 Interventions to improve treatment adherence in migrant people living with HIV in the Netherlands: feasibility and efficacy Been
P29 Protease inhibitor resistance after failure of second line therapy in a rural South African setting Hermans
P30 Risk factors for HGAIN among HIV-positive MSM in Amsterdam, the Netherlands Siegenbeek van Heukelom
P31 No evidence of differences in anal HPV 16/18 load between HIV-positive and HIV-negative MSM Marra
P32 Persistent anal hr-HPV as biomarker for predicting HGAIN in HIV-infected MSM Marra
P33 HIV infection is independently associated with chronic kidney disease and mild glomerular hyperfiltration, particularly in those of African descent Kooij
P34 Verification and Evaluation of Neurocognitive screening and Monitoring in HIV-patients (VENOM) Kraaijenhof
P35 Prevalence of cardiovascular risk factors among HIV-infected and –uninfected women in the reproductive age Harmsen
P36 Tuberculosis patients with unknown HIV status in the Netherlands: analysing underreporting and lack of testing Arnoldussen
P37 The influence of HIV infection and respiratory risk factors on pulmonary condition in HIV-infected individuals in Sub-Saharan Africa Varkila
P38 Exploring communities and community-based care programmes innovations in leveraging care for chronic conditions at primary healthcare in Southern Malawi: A mixed-methods study Angwenyi
P39 Endothelial activation and inflammation associated with microstructural white matter injury and poor visuomotor integration in HIV-infected children van Zanten
P40 Elevated systemic IL-15, IFN?, IP-10, and MCP-1 do not correlate with intrathecal inflammation in cART-treated perinatally HIV-infected children Blokhuis
P41 Higher subcortical and white matter cerebral blood flow in perinatally HIV-infected children Blokhuis
P42 Prevalence and patient characteristics of noninvasively measured liver fibrosis in cART-treated perinatally HIV-1-infected children Blokhuis
P43 The role of CMV and the need for appropriate HIV-uninfected controls to evaluate T-cell senescence in HIV-positive individuals on combination antiretroviral therapy. Booijman
P44 Development and validation of the HCV-MOSAIC risk score to assist testing for acute HCV infection in HIV-infected MSM Newsum
P45 Lack of compliance to hepatocellular carcinoma (HCC) screening guidelines in hepatitis B (HBV) or C (HCV) virus co-infected HIV patients with cirrhosis; COHERE in Eurocoord Smit
P46 Effect of hepatitis C virus infection and its timing relative to HIV seroconversion on CD4 T-cell and HIV RNA trends among HIV-positive MSM van Santen

Aids Fonds high-risk, high-gain pitch presentations

View the full presentation here.